Effects of Insulin Treatment on Postprandial Platelet Activation in Patients With NIDDM: a Placebo-Controlled Dose-Response Study With Insulin Aspart (Novorapid).

Trial Profile

Effects of Insulin Treatment on Postprandial Platelet Activation in Patients With NIDDM: a Placebo-Controlled Dose-Response Study With Insulin Aspart (Novorapid).

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Jun 2011

At a glance

  • Drugs Insulin aspart (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Acronyms NIDDM
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 04 Nov 2010 Actual end date (Aug 2010) added as reported by ClinicalTrials.gov.
    • 04 Nov 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top